The mRNA Cancer Vaccine: The Dawn of Personalised Oncology

From Science Fiction to Standard Therapy

Jedd Wolchok, director of the Meyer Cancer Center at Weill Cornell Medicine, described the achievement as establishing personalised cancer vaccines as a new addition to standard cancer therapy. He pointed out that the idea of producing a vaccine from the sequencing of an individual tumour once sounded like science fiction.

That shift is bigger than one melanoma treatment.

Researchers are already testing personalised mRNA cancer vaccines against lung, kidney, bladder, pancreatic, stomach and colorectal cancers. Moderna and Merck are conducting additional studies, while other research groups are exploring the same neoantigen strategy across different tumour types.

Catherine Wu of Dana-Farber Cancer Institute has described it as highly conceivable that the treatment paradigm could be extended to other cancers.

The reason is fundamental: the platform does not depend on one particular cancer mutation. It is designed to identify the mutations belonging to the patient sitting in front of the doctor and build a treatment around them.

Click "Allow" to continue